9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma

Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma

Estimated reading time: < 1 min

Condition: Malignant Peritoneal Mesothelioma

Estimated Enrollment: 2

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: Has Results

Outcome Measures: Objective Response Rate,  PFS,  OS, Toxicity

Interventions: erlotinib hydrochloride,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: February 2017

Completion Date: February 2017

Last  Posted Date: October 16, 2018

Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Website Link: https://ClinicalTrials.gov/show/NCT01592383

Was this article helpful?
Dislike 0